Objective: There is no standard method to establish an early diagnosis of lower extremity lymphedema (LEL). Lower extremity lymphedema can be diagnosed by physical examination and laboratory tests when patients complain of typical clinical symptoms. The objective of this study was to investigate the incidence and risk factors of LEL in patients with ovarian cancer.
Methods: The medical records were reviewed retrospectively in patients with ovarian cancer treated at Seoul St. Mary's Hospital from January 2000 to July 2014.
Results: A total of 413 patients with epithelial ovarian cancer were analyzed. Forty-six patients (11.1%) developed LEL, and 67.4% of these patients had LEL within 1 year after surgery. The mean number of resected lymph nodes (LNs) was larger in patients with LEL (43.1 ± 16.7; range, 12-80) than in those without (32.3 ± 19.8; range, 0-99) (P < 0.0001). The number of resected LNs was significantly associated with the occurrence of LEL (odds ratio, 1.025; 95% confidence interval, 1.005-1.045; P < 0.05).
Conclusion: A significant proportion of patients with ovarian cancer could develop LEL after surgery. This study suggests that the occurrence of LEL is associated with the number of resected LNs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IGC.0000000000000757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between hormone therapy and glioma risk in US women: a cancer screening trial.
Menopause
January 2025
From the Department of Neurosurgery, Chongqing General Hospital, Chongqing University, Chongqing, China.
Objective: Gliomas are the most common primary brain tumors in adults, and the role of hormone therapy (HT) in their development remains controversial. This study with a cohort design aimed to investigate the association between HT use and glioma risk using the data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Methods: We analyzed data from 75,335 women, aged 50-78, who were enrolled between 1993 and 2001.
Ovarian Carcinomas: Clinicopathologic and Molecular Features With Comments on 2014 FIGO Staging.
Am J Surg Pathol
January 2025
Department of Medical and Biotechnological Sciences, University "G. D'Annunzio", Via dei Vestini, Chieti-Pescara Italy.
According to histopathology and molecular genetics, there are 5 major subtypes of ovarian carcinomas: high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3% to 4%), and low-grade serous (<5%) carcinomas. These tumors, which constitute over 95% of cases, represent distinct diseases with different prognoses and therapy. This review outlines contemporary advances in molecular pathology, which have expanded our knowledge of the biology of epithelial ovarian cancer and are also important to patient management.
View Article and Find Full Text PDFTRIB1 facilitates the proliferation and migration of ovarian cancer cells by inducing EMT progression.
Histol Histopathol
December 2024
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
Aim: Ovarian cancer (OC) is a fatal female malignant tumor that severely impacts the health of women worldwide. Due to the lack of diagnostic biomarkers, 70% of OC patients are considered in the advanced stage at the first diagnosis. Exploring novel biomarkers for OC diagnosis has become an urgent clinical need to address.
View Article and Find Full Text PDFAnalysis of endometrial liquid‑based cytology samples to detect somatic mutations and classify ovarian cancer.
Oncol Lett
March 2025
Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie 514-8507, Japan.
Ovarian cancer has a poor prognosis, and screening methods have not been established. Biomarkers based on molecular genetic characteristics must be identified to develop diagnostic and therapeutic strategies for all cancer types, particularly ovarian cancer. The present study aimed to evaluate the usefulness of genetic analysis of cervical and endometrial liquid-based cytology (LBC) specimens for detecting somatic mutations in patients with ovarian cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!